Outcome of the Board Meeting and submission of Audited Financial Results for the quarter and year ended 31st March 2026
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
IOL Chemicals & Pharmaceuticals reported standalone revenue of Rs 2,319 crore for FY26, up 11.5% from Rs 2,079 crore in FY25. Profit after tax grew 36% to Rs 137.72 crore from Rs 101 crore. EPS improved to Rs 4.69 from Rs 3.44. The board fixed the 39th AGM for September 2, 2026. The auditors issued an unmodified (clean) opinion on the financial statements. The company announced expansion plans: new Triacetin manufacturing facility with 6,000 MTPA capacity (Rs 16.88 crore capex) and Pantoprazole capacity increase from 240 to 276 MTPA (Rs 5.87 crore capex), both funded through internal accruals. An exceptional item of Rs 11.21 crore was recorded for past service cost due to new Labour Code amendments.
Strong bottom-line growth with 36% PAT increase and clean audit opinion signals financial health. New capacity expansions in Triacetin and Pantoprazole could support future revenue growth while existing cash-funded capex maintains balance sheet strength.